PH12018500980A1 - Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor - Google Patents

Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor

Info

Publication number
PH12018500980A1
PH12018500980A1 PH12018500980A PH12018500980A PH12018500980A1 PH 12018500980 A1 PH12018500980 A1 PH 12018500980A1 PH 12018500980 A PH12018500980 A PH 12018500980A PH 12018500980 A PH12018500980 A PH 12018500980A PH 12018500980 A1 PH12018500980 A1 PH 12018500980A1
Authority
PH
Philippines
Prior art keywords
preparation
method therefor
oral use
containing solid
amorphous solifenacin
Prior art date
Application number
PH12018500980A
Inventor
Ho Taek Im
Taek Kwan Kwon
Seung Bin Youn
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PH12018500980A1 publication Critical patent/PH12018500980A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An aspect of the present invention provides a solid preparation for oral administration, containing: amorphous solifenacin or a pharmaceutically acceptable salt thereof; and a stabilizer selected from the group consisting of alkane celluloses, antioxidants, and any combination thereof.
PH12018500980A 2015-11-11 2018-05-07 Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor PH12018500980A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150158108A KR20170055211A (en) 2015-11-11 2015-11-11 Solid formulation for oral administration containing amorphous solifenacin and a process for the preparation thereof
PCT/KR2016/012490 WO2017082577A1 (en) 2015-11-11 2016-11-02 Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor

Publications (1)

Publication Number Publication Date
PH12018500980A1 true PH12018500980A1 (en) 2019-01-28

Family

ID=58695652

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018500980A PH12018500980A1 (en) 2015-11-11 2018-05-07 Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor

Country Status (7)

Country Link
KR (1) KR20170055211A (en)
CN (1) CN108348617A (en)
BR (1) BR112018009413A2 (en)
EA (1) EA201890896A1 (en)
MX (1) MX2018005848A (en)
PH (1) PH12018500980A1 (en)
WO (1) WO2017082577A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180003340A (en) * 2016-06-30 2018-01-09 한미약품 주식회사 Solid formulation for oral administration containing amorphous solifenacin and a process for the preparation thereof
KR20200078121A (en) 2018-12-21 2020-07-01 한미약품 주식회사 Composite formulation for oral administration comprising Tamsulosin and Solifenacin and a process for the preparation thereof
KR20200121183A (en) 2019-04-15 2020-10-23 한미약품 주식회사 Composite formulation comprising Tamsulosin and Solifenacin and a process for the preparation thereof
KR20210114271A (en) 2020-03-10 2021-09-23 주식회사 종근당 Pharmaceutical composition comprising solifenacin or its pharmaceutically acceptable salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
JP4816828B2 (en) * 2009-03-30 2011-11-16 アステラス製薬株式会社 Solid pharmaceutical composition containing amorphous solifenacin
KR20150092385A (en) * 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 Stable pharmaceutical composition comprising solifenacin, and method for preparing the same
KR20150102852A (en) * 2014-02-28 2015-09-08 대원제약주식회사 Solid dispersion composition with increased stability comprising amorphous solifenacin or pharmaceutically acceptable salts thereof
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition

Also Published As

Publication number Publication date
BR112018009413A2 (en) 2018-12-04
KR20170055211A (en) 2017-05-19
WO2017082577A1 (en) 2017-05-18
EA201890896A1 (en) 2018-10-31
CN108348617A (en) 2018-07-31
MX2018005848A (en) 2019-07-18

Similar Documents

Publication Publication Date Title
MY197700A (en) Compounds useful for inhibiting cdk7
MX2016016593A (en) Novel aminoalkyl benzothiazepine derivative and use thereof.
PH12018500047B1 (en) Notch pathway signaling inhibitor compounds
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
EP4219526A3 (en) Method for preparing amg 416
PH12018500980A1 (en) Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor
GB201903767D0 (en) Multimers, tetramers & octamers
ZA201708234B (en) Delivery systems for controlled drug release
EP3297678A4 (en) An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
MX2017004808A (en) Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3752149A4 (en) Quinolone analogs and their salts, compositions, and method for their use
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
EA033314B1 (en) ANTIBACTERIALS COMPRISING PYRAZINO[2,3-b][1,4]OXAZIN-3-ONE OR A RELATED RING SYSTEM
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
MA39877A (en) Solid forms of a pharmaceutically active compound
TW201613581A (en) Pharmaceutical composition for suppression of thromboembolization after stent placement
UA124942C2 (en) Process for the preparation of pirlindole enantiomers and its salts
MX2018007326A (en) Composition for reducing frequency of urination, method of making and use thereof.
EP3256131A4 (en) Analogs of 3,5-dihydroxypentanoate for bone formation
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof